Skip to content

BIO INX

Active
Private limited companyfounded 20224 yrs activeTechnologiepark-Zwijnaarde 66, 9052 Gent, BelgiumKBO/BCE: BE 0784.459.685
Summary

The annual accounts of BIO INX for fiscal year 2024 show a net loss of 152% of the equity at the start of that year. The 2024 annual accounts show equity of €49,332 and a net result of -€294,805. Its solvency ranks better than 18% of 226 sector peers (fiscal year 2024). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 1.2% (low).

Checked score

Score 2024
Axes · tick = 2023
Profitability0=
Solvency28▼-45
Growth58
Track record94
Bankruptcy probability, 12 months
1.2% Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2,000 at 30 days only on tighter terms
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity ample (current ratio 5.52 against 3.03 in 2023; short-term debt: 14.5% and cash: 22% of total assets), but 97.2% of the assets are financed with debt.
Credit check for your own amount and term

Open the credit simulator : see how the verdict changes with amount, term and advance.

Signals

Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 4 years 0 10 y
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2024
Solvency, return and age of the figures
Solvency
2.8%
Return on assets
-17%
Age of the figures
21 mo
raises risk · Persistent losses
Two consecutive loss-making years (2023 and 2024); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2024
Net result per financial year
2324
2023 to 2024 · latest year -€294,805
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 18% of 226 sector peers (2024).
NBB · sector comparison
Position among 226 sector peers
Solvency
better than 18%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 10-07-2025, 21 days ahead of the deadline.
NBB · 2 filings
Deviation from the deadline
2025
not confirmed
2024
21 d early
2023
22 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 2 accounts on average 22 days before the deadline; the sector median for financial year 2024 is 13 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

On 4 April 2022, BIO INX was incorporated as a Private limited company.1 The company has filed 2 sets of annual accounts, the latest for fiscal year 2024.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2024

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2024, abbreviated schema

Equity
€49,332▼ 74.6%
2023 · €194,137
Total assets
€1.7m▲ 332%
2023 · €402,394
Net result
-€294,805▲ 11.1%
2023 · -€331,463
Working capital
€1.1m▲ 543%
2023 · €176,504
Trend over the years

Click a name to add, emphasise or remove a line.

Every figure with its change against the fiscal year before
favourable unfavourable
Line20232024
Operating result-€329,814--€279,697▲ 15.2%
Net result-€331,463--€294,805▲ 11.1%
Equity€194,137-€49,332▼ 74.6%
Total assets€402,394-€1.7m▲ 332%
Debt€208,257-€1.7m▲ 711%
Working capital€176,504-€1.1m▲ 543%
Staff (FTE)1.8-2.8▲ 55.6%
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Why a figure moved sharply
  • 2024 Equity -75%, Total assets +332% on 2023. Cause not known from the registers.
Result per fiscal year
Operating resultNet result
-€400,000-€300,000-€200,000-€100,000€0Operating result 2023: -€329,814-€329,814Net result 2023: -€331,463-€331,463Operating result 2024: -€279,697-€279,697Net result 2024: -€294,805-€294,80520232024-€400,000-€300,000-€200,000-€100,000€0Operating result 2023: -€329,814-€330,000Net result 2023: -€331,463-€331,000Operating result 2024: -€279,697-€280,000Net result 2024: -€294,805-€295,00020232024
The operating result stays negative: a loss of €279,697 in 2024 against €329,814 in 2023; the loss shrinks.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €1.7m
Fixed assets €352,151 ▲ 153%
Current assets €1.4m ▲ 427%
Equity and liabilities €1.7m
Equity €49,332 ▼ 74.6%
Debt €1.7m ▲ 711%
Debt's share of the balance-sheet total rises from 51.8% to 97.2%. Equity is lower and debt is higher.
Key figures and ratios
2024 value · change against 2023
EBITDA
-€194,169▲
2023 · -€272,268
Cash flow
-€209,278▲
2023 · -€273,917
Current ratio
5.52▲
2023 · 3.03
Quick ratio
5.44▲
2023 · 3.03
Debt to equity
34.24▲
2023 · 1.07
ROE
-597.6%▼
2023 · -170.7%
ROA
-17.0%▲
2023 · -82.4%
Interest coverage
-11.67▲
2023 · -156.03
Debt ≤ 1 year
€251,295▲
2023 · €86,757
Debt > 1 year
€196,626
Staff costs
€126,554▼
2023 · €149,994
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 759 companies that looked in July 2024 the way this one looks now, 7.5% went bankrupt within 24 months and 86% are still going.

  • Micro
  • 2 to 5 years old
  • solvency under 10%
  • a loss of 10% of the balance sheet or more
7.5% went bankrupt
4.5% stopped otherwise
86% still going

A further 1.7% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a lower bankruptcy probability: 1.2% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.4%
3 0.5% 0.5%
4 0.6% 0.7%
5 0.8% 0.9%
6 1.2% 1.3%
7 1.5% 1.6%
8 1.7% 1.7%
9 2.7% 2.8%
10 5.3% 5.7%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 759 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2024 against 2023 · 50 lines
Balance sheet Code20232024
Assets
Total assets20/58€402,394€1.7m▲
Fixed assets21/28€139,133€352,151▲
Intangible fixed assets21€5,038€13,291▲
Tangible fixed assets22/27€134,095€338,860▲
Plant, machinery and equipment23€123,121€88,083▼
Furniture and vehicles24€4,640€2,754▼
Leasing and similar rights25-€248,024
Assets under construction and advance payments27€6,334-
Current assets29/58€263,261€1.4m▲
Amounts receivable after more than one year29-€662,968
Other amounts receivable291-€662,968
Stocks and contracts in progress3-€20,120
Stocks30/36-€20,120
Amounts receivable within one year40/41€194,563€300,566▲
Trade receivables40€193,495€9,104▼
Other amounts receivable41€1,067€291,462▲
Cash at bank and in hand54/58€61,202€381,754▲
Deferred charges and accrued income490/1€7,496€21,037▲
Equity and liabilities
Total equity and liabilities10/49€402,394€1.7m▲
Equity10/15€194,137€49,332▼
Contributions10/11€525,600€675,600▲
Profit (loss) carried forward14-€331,463-€626,268▼
Amounts payable17/49€208,257€1.7m▲
Amounts payable after more than one year17-€196,626
Financial debts170/4-€196,626
Amounts payable within one year42/48€86,757€251,295▲
Current portion of amounts payable after more than one year42-€38,395
Trade debts44€46,557€52,602▲
Suppliers440/4€46,557€52,602▲
Taxes, remuneration and social security45€36,355€9,905▼
Taxes450/3€17,167-
Remuneration and social security454/9€19,187€9,905▼
Other amounts payable47/48€3,846€150,393▲
Accrued charges and deferred income492/3€121,500€1.2m▲
Income statement Code20232024
Non-recurring operating income76A€174€19,500▲
Remuneration, social security and pensions62€149,994€126,554▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€57,546€85,528▲
Other operating charges640/8€1,349€915▼
Gross operating margin9900-€120,925-€66,700▲
Operating profit (loss)9901-€329,814-€279,697▲
Financial income75/76B€96€1,537▲
Recurring financial income75€96€1,537▲
Financial charges65/66B€1,745€16,645▲
Recurring financial charges65€1,745€16,645▲
Profit (loss) for the period before taxes9903-€331,463-€294,805▲
Profit (loss) for the period9904-€331,463-€294,805▲
Profit (loss) for the period to be appropriated9905-€331,463-€294,805▲
Appropriation of the result
Profit (loss) to be appropriated9906-€331,463-€626,268▼
Profit (loss) brought forward from the previous period14P--€331,463
Social balance
Average headcount (FTE)9087-2.8

The notes to these accounts (17 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20232024Change
Non-recurring operating income76A€174€19,500▲ 11,128%
Remuneration, social security and pensions62€149,994€126,554▼ 15.6%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€57,546€85,528▲ 48.6%
Other operating charges640/8€1,349€915▼ 32.2%
Gross operating margin9900-€120,925-€66,700▲ 44.8%
Operating profit (loss)9901-€329,814-€279,697▲ 15.2%
Financial income75/76B€96€1,537▲ 1,500%
Recurring financial income75€96€1,537▲ 1,500%
Financial charges65/66B€1,745€16,645▲ 854%
Recurring financial charges65€1,745€16,645▲ 854%
Profit (loss) for the period before taxes9903-€331,463-€294,805▲ 11.1%
Profit (loss) for the period9904-€331,463-€294,805▲ 11.1%
Profit (loss) for the period to be appropriated9905-€331,463-€294,805▲ 11.1%
Line20232024Change
Assets
Total assets20/58€402,394€1.7m▲ 332%
Fixed assets21/28€139,133€352,151▲ 153%
Intangible fixed assets21€5,038€13,291▲ 164%
Tangible fixed assets22/27€134,095€338,860▲ 153%
Plant, machinery and equipment23€123,121€88,083▼ 28.5%
Furniture and vehicles24€4,640€2,754▼ 40.7%
Leasing and similar rights25-€248,024-
Assets under construction and advance payments27€6,334--
Current assets29/58€263,261€1.4m▲ 427%
Amounts receivable after more than one year29-€662,968-
Other amounts receivable291-€662,968-
Stocks and contracts in progress3-€20,120-
Stocks30/36-€20,120-
Amounts receivable within one year40/41€194,563€300,566▲ 54.5%
Trade receivables40€193,495€9,104▼ 95.3%
Other amounts receivable41€1,067€291,462▲ 27,203%
Cash at bank and in hand54/58€61,202€381,754▲ 524%
Deferred charges and accrued income490/1€7,496€21,037▲ 181%
Equity and liabilities
Total equity and liabilities10/49€402,394€1.7m▲ 332%
Equity10/15€194,137€49,332▼ 74.6%
Contributions10/11€525,600€675,600▲ 28.5%
Profit (loss) carried forward14-€331,463-€626,268▼ 88.9%
Amounts payable17/49€208,257€1.7m▲ 711%
Amounts payable after more than one year17-€196,626-
Financial debts170/4-€196,626-
Amounts payable within one year42/48€86,757€251,295▲ 190%
Current portion of amounts payable after more than one year42-€38,395-
Trade debts44€46,557€52,602▲ 13.0%
Suppliers440/4€46,557€52,602▲ 13.0%
Taxes, remuneration and social security45€36,355€9,905▼ 72.8%
Taxes450/3€17,167--
Remuneration and social security454/9€19,187€9,905▼ 48.4%
Other amounts payable47/48€3,846€150,393▲ 3,811%
Accrued charges and deferred income492/3€121,500€1.2m▲ 922%
Line20232024Change
Profit (loss) for the period9904-€331,463-€294,805▲ 11.1%
+ Depreciation and write-downs630€57,546€85,528▲ 48.6%
Operating cash flow (approximation)-€273,917-€209,278▲ 23.6%
Investment in fixed assets (approximation)--€298,546-
Change in cash-€320,552-

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

2025
10-07
NBB filing Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
09-07
NBB filing Annual accounts filed
fiscal year 2023 · micro schema
NBB filing
0 of 6 acts read
About the unread acts

We know of 6 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
6 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Gent · 1 establishment unit since 2022
seat establishment The establishment unit on the map
Ground area
3,522 m²
Building footprint
1,677 m²
Volume, LiDAR
12,330 m³
Parcel 44082B0141/00G000, Flanders · tallest building 20.3 m, ±2 floors. Linked by address, not a title deed.
3 companies at this address See who is registered here
1 establishment unit
Bio Inx
Technologiepark-Zwijnaarde 66, 9052 GentOther printing
since 20222.340.340.774
1 parcel
Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
44082B0141/00G000 Flanders 3,522 m² 1 · 1,677 m² 20.3 m · 2 fl.
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Structure & network

Owners and holdings

1 owner

Owners 1

Holdings 0

No holding stated in the accounts, acts or LEI register we read.

According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.

Connections & network

No current directors or connected companies found in the register.

Public money · subsidies and aid

Flemish government

2022 to 2025 · 17 entries · 666,489 EUR awarded · 567,780 EUR paid
Year Entries awardedpaid
2025 8 -10,762 EUR179,355 EUR
2024 2 0 EUR153,000 EUR
2023 4 229,150 EUR234,000 EUR
2022 3 448,101 EUR1,425 EUR
Schemes
5 entries · 246,671 EUR · 195,000 EUR paid · Fonds voor Innoveren en Ondernemen
4 entries · 220,150 EUR · 176,000 EUR paid · Fonds voor Innoveren en Ondernemen
4 entries · 170,293 EUR · 170,293 EUR paid · Fonds voor Innoveren en Ondernemen
2 entries · 25,062 EUR · 25,062 EUR paid · Vlaams Agentschap voor Internationaal Ondernemen
2 entries · 4,313 EUR · 1,425 EUR paid · Fonds voor Innoveren en Ondernemen

European Union, budget

2024 · 2 entries · 696,498 EUR in total
Year Entries awarded
2024 2 696,498 EUR
Projects
LUMINATE - LIGHTING THE WAY TOWARDS IN SITU OSTEOCHONDRAL REGENERATION THROUGH MICROEXTRUSION AND FILAMENTED LIGHT BIOPRINTING
Horizon Europe · 01-01-2025 to 31-12-2028 · 696,498 EUR

European research

1 project · 696,500 EUR EU contribution
Programmes
1 entry · 696,500 EUR
Projects
LIGHTING THE WAY TOWARDS IN SITU OSTEOCHONDRAL REGENERATION THROUGH MICROEXTRUSION AND FILAMENTED LIGHT BIOPRINTING
Horizon Europe · participant · 01-01-2025 to 31-12-2028 · 696,500 EUR · LUMINATE

Recognitions · licences · registrations

Food safety, FASFC

1 site
Gent2.340.340.774
1 permission
Toelating · Groothandelaar levensmiddelen · since 09-09-2024

Similar companies · same sector, comparable size

Of 762 companies in sector 72101 we hold annual accounts for 483. 240 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPrivate limited company
Founded04-04-2022
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
Contact
Phone +32499169894
E-invoicing
Reachable via Peppol
Peppol ID 0208:0784459685

Register as of 27 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.